Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.72, $0.06 worse than the analyst estimate of $0.78. Revenue for the quarter came in at $163.93 million versus the consensus estimate of $173.42 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.